# Wuhan Binhui Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuhan-binhui-biotechnology-co

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.binhui-bio.com.cn
- Total disclosed funding: $144M
- Latest round: Series B (Apr 18, 2022)
- Investors on record: 10

## About

Established in 2010 and based in Wuhan, China, BinHui Biotech operates as a biomedical company that focuses on the oncolytic virus immunotherapy field. The company's founder and chairman, Binlei Liu, has a PhD in molecular viruses from the University of Southampton in the UK, and has more than 20 years of experience in tumor immunity and lysosomal virus research. It has partnerships with Atagenix, Hong Tough Pharmaceuticals and Sugar Smart Pharmaceuticals. In April 2024, it closed a strategic funding.

The company developed oHSV2 that monotherapy kills tumor cells directly and activates immune response through specific targeting and replication based on oncoytic virus platform. The company also developed recombinant protein vaccine, and nucleic acid vaccine, based on the vaccine R&D platform. Its first product has obtained three Investigational New Drug (IND) approvals for OV mono and combo therapies. Also, in August 2021, the BS001(OH2) injection was approved by the Food and Drug Administration (FDA) for the clinical trial of various indications in the US, such as esophageal cancer, melanoma, glioblastoma.

The company generates revenue by advancing its innovative oncolytic virus drugs through clinical trials and towards commercialization. 

The company will use the strategic funding to advance core pipeline clinical trials and lysosomal virus drug development.

## Funding rounds

- Series B, Apr 18, 2022, $47M — Hubei High Technology, DNV Capital, Ming Capital, Jointown Pharmaceutical Group, Yangtze River Pharmaceutical Group Co.,Ltd.
- Series B, Feb 10, 2021, $93M — Temasek Holdings, China International Capital Corporation, Share Capital, Lapam Capital, Chengdu Qianhai FOF
- Seed, Jun 1, 2017, $3.9M — Lapam Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Seed, Series B
- Temasek Holdings — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- Share Capital (https://capitalatlas.ai/funds/share-capital) — Series B
- Chengdu Qianhai FOF — Series B
- Hubei High Technology (https://capitalatlas.ai/funds/hubei-high-technology) — Series B
- DNV Capital (https://capitalatlas.ai/funds/dnv-capital) — Series B
- Ming Capital — Series B
- Jointown Pharmaceutical Group — Series B
- Yangtze River Pharmaceutical Group Co.,Ltd. — Series B